People with impaired glucose tolerance who received metformin or intensive lifestyle intervention during the DPP trial show no sign of a significantly reduced cardiovascular disease risk 21 years later, reveal the latest DPPOS results.
People who start SGLT2 inhibitors as a first-line diabetes treatment have a reduced risk for heart failure hospitalization relative to those who start metformin and a similar risk for other vascular outcomes, a study shows.
People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.
The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.
The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.
Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.